Crick — Clinical Intelligence Platform

Not applicableLooking for participantsNCT05584722

What this trial is testing

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Who this might be right for

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionUnaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo+1 more

Vanderbilt University Medical Center

Results for “Healthy Volunteers, Pulmonary Arterial Hypertension”

The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects

Water- and Salt-homeostasis in Healthy Humans, and in Patients With Heart- or Lung Disease

Integrating ePReBMs From Phoenix in Respiratory Diseases

Endothelial Cell Dysfunction in Pulmonary Hypertension

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Subcutaneous Elafin in Healthy Subjects

Preliminary Testing of the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058

To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers

Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)

Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects